24828
Four breakpoint cluster region ( BCR ) - ABL1 tyrosine kinase inhibitors ( TKIs ) are currently available for the treatment of chronic myeloid leukemia ( CML ) : imatinib , nilotinib , dasatinib , and bosutinib .
 tyrosine, imatinib, nilotinib, dasatinib, bosutinib
Please list all entity words in the text that fit the category. Output format is "word1, word2". 
Option: Chemical 
Text: {0} 
Answer:
 tyrosine, imatinib, nilotinib, dasatinib, bosutinib